Table 1.
Demographic and baseline characteristics and isolated pathogens of patients with CAP at index hospitalization
| Characteristic | Patients (n = 185) |
|---|---|
| Age, years, n (%) | |
| >90 | 3 (1.6) |
| ≤90 | 182 (98.4) |
| Mean (SD) | 62.2 (18.9) |
| ≤65 | 90 (48.6) |
| >65 | 95 (51.4) |
| Sex, n (%) | |
| Male | 109 (58.9) |
| Female | 76 (41.1) |
| Country, n (%) | |
| France | 16 (8.6) |
| Greece | 53 (28.6) |
| Italy | 24 (13.0) |
| Spain | 54 (29.2) |
| Russia | 25 (13.5) |
| Brazil | 6 (3.2) |
| Colombia | 7 (3.8) |
| Weight, kg, mean (SD)a | 74.0 (19.4) |
| BMI, kg/m2, mean (SD)b | 26.1 (6.2) |
| Type of residence/cohabitation pre-index admission, n (%)c | |
| Nursing home or extended-care facility | 8 (4.3) |
| Living independently | 122 (65.9) |
| Living with care support (family, friend, hired support) | 46 (24.9) |
| Other | 1 (0.5) |
| Smoking habits, n (%) | |
| Non-smoker | 71 (38.4) |
| Ex-smoker (stopped ≥365 days ago) | 38 (20.5) |
| Occasional smoker (<1 tobacco product per day) | 4 (2.2) |
| Habitual smoker (≥1 tobacco products per day) | 38 (20.5) |
| Unknown | 34 (18.4) |
| qSOFA conducted, n (%) | |
| Yes | 74 (40.0) |
| qSOFA component assessment, n (%) | |
| Glasgow coma scale <15 | 15 (20.3) |
| Systolic blood pressure <100 mmHg | 15 (20.3) |
| High respiration rate (≥22 breaths per min) | 45 (60.8) |
| Patient required isolation, n (%) | |
| Yes | 20 (10.8) |
| Duration of isolation, days, mean (SD) | 16.5 (14.0) |
| Isolated pathogens, n (%) | |
| S. pneumoniae | 44 (23.8) |
| S. aureus (all) | 33 (17.8) |
| MRSA | 14 (7.6) |
| MSSA | 15 (8.1) |
| Methicillin susceptibility not reported | 4 (2.2) |
| Klebsiella pneumoniae | 3 (1.6) |
| Haemophilus influenzae | 3 (1.6) |
| Legionella spp.d | 2 (1.1) |
| Escherichia coli | 2 (1.1) |
| Haemophilus parainfluenzae | 1 (0.5) |
| P. aeruginosad | 1 (0.5) |
| Other/unknown/none of the above | 113 (61.1) |
a n = 90 (data not available for 95 patients).
b n = 79 (data not available for 106 patients).
c n = 177 (data not available for eight patients).
dNot susceptible to ceftaroline fosamil.